PURPOSE: Circumstantial evidence suggests that development of uveal melanoma may be associated to two different pathogenetic pathways, either loss of chromosome 3 or extra copies of 6p (+6p). Chromosome 3 monosomy (-3) is detected in approximately half of uveal melanomas, and is strongly linked to metastatic disease, whereas +6p accounts for one-fourth of uveal melanomas with no clear clinical correlations. The aim of our study was to verify if the analysis of chromosomes 3 and 6 was able to distinguish two groups of patients for translating this approach in the clinical practise as prognostic tool. METHODS: Fluorescence in situ hybridisation (FISH) with probes for chromosome 3, 6p and 6q was used to analyze cytological material obtained by fine needle aspiration biopsy (FNAB) from 28 primary uveal melanomas, just before brachytherapy. RESULTS: Abnormalities affecting 6p and 6q were found in 14 tumors (50%), and -3 in 16 cases (57%). Interestingly, -3 and +6p were mutually exclusive in 23 cases (82%), whereas in two cases only (7%) they coexisted. In particular, +6p alone was present in 9 lesions (32%), -3 was the sole aberration in 11 cases (39%), and concomitant -3 and -6q in 3 other cases (11%). CONCLUSIONS: Although the patient cohort is limited, our findings confirm the hypothesis of a bifurcated pathogenetic model of uveal melanoma. Moreover, our results suggest that investigation of both markers on FNAB samples obtained in vivo could provide a clearer clinical picture of genetic lesions when no histological material is available for prognostic evaluation.
PURPOSE: Circumstantial evidence suggests that development of uveal melanoma may be associated to two different pathogenetic pathways, either loss of chromosome 3 or extra copies of 6p (+6p). Chromosome 3 monosomy (-3) is detected in approximately half of uveal melanomas, and is strongly linked to metastatic disease, whereas +6p accounts for one-fourth of uveal melanomas with no clear clinical correlations. The aim of our study was to verify if the analysis of chromosomes 3 and 6 was able to distinguish two groups of patients for translating this approach in the clinical practise as prognostic tool. METHODS: Fluorescence in situ hybridisation (FISH) with probes for chromosome 3, 6p and 6q was used to analyze cytological material obtained by fine needle aspiration biopsy (FNAB) from 28 primary uveal melanomas, just before brachytherapy. RESULTS: Abnormalities affecting 6p and 6q were found in 14 tumors (50%), and -3 in 16 cases (57%). Interestingly, -3 and +6p were mutually exclusive in 23 cases (82%), whereas in two cases only (7%) they coexisted. In particular, +6p alone was present in 9 lesions (32%), -3 was the sole aberration in 11 cases (39%), and concomitant -3 and -6q in 3 other cases (11%). CONCLUSIONS: Although the patient cohort is limited, our findings confirm the hypothesis of a bifurcated pathogenetic model of uveal melanoma. Moreover, our results suggest that investigation of both markers on FNAB samples obtained in vivo could provide a clearer clinical picture of genetic lesions when no histological material is available for prognostic evaluation.
Authors: K Sisley; I G Rennie; M A Parsons; R Jacques; D W Hammond; S M Bell; A M Potter; R C Rees Journal: Genes Chromosomes Cancer Date: 1997-05 Impact factor: 5.006
Authors: Nicole C Naus; Anette C A Verhoeven; Ellen van Drunen; Rosalyn Slater; Cornelia M Mooy; Dion A Paridaens; Grégorius P M Luyten; Annelies de Klein Journal: Clin Cancer Res Date: 2002-02 Impact factor: 12.531
Authors: Mattias Höglund; David Gisselsson; Gunnar B Hansen; Valerie A White; Torbjörn Säll; Felix Mitelman; Douglas Horsman Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Michael D Onken; Lori A Worley; Erica Person; Devron H Char; Anne M Bowcock; J William Harbour Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Arun D Singh; Mary E Aronow; Yang Sun; Gurkan Bebek; Yogen Saunthararajah; Lynn R Schoenfield; Charles V Biscotti; Raymond R Tubbs; Pierre L Triozzi; Charis Eng Journal: Invest Ophthalmol Vis Sci Date: 2012-06-05 Impact factor: 4.799
Authors: Rhydian Caines; Antonio Eleuteri; Helen Kalirai; Anthony C Fisher; Heinrich Heimann; Bertil E Damato; Sarah E Coupland; Azzam F G Taktak Journal: Mol Vis Date: 2015-01-12 Impact factor: 2.367
Authors: Mark J de Lange; Sake I van Pelt; Mieke Versluis; Ekaterina S Jordanova; Wilma G M Kroes; Claudia Ruivenkamp; Sjoerd H van der Burg; Grégorius P M Luyten; Thorbald van Hall; Martine J Jager; Pieter A van der Velden Journal: Oncotarget Date: 2015-11-10